Table 1.
Included trials/treatments and important comedications and inclusion criteria
| Study name or code | Interventions | Number randomized | Received concomitant LAMA | Received concomitant xanthines | Received concomitant SAMA | GOLD stage IV at baseline |
|---|---|---|---|---|---|---|
| 1222.11 | Olodaterol 5 mcg | 208 | 21% | 14% | 22% | 14% |
| Olodaterol 10 mcg | 207 | 25% | 15% | 20% | 10% | |
| Placebo | 209 | 25% | 14% | 20% | 12% | |
| 1222.12 | Olodaterol 5 mcg | 209 | 16% | 12% | 14% | 11% |
| Olodaterol 10 mcg | 217 | 22% | 10% | 18% | 12% | |
| Placebo | 216 | 18% | 12% | 19% | 17% | |
| 1222.13 | Olodaterol 5 mcg | 227 | 26% | 15% | 34% | 6% |
| Olodaterol 10 mcg | 225 | 26% | 15% | 26% | 9% | |
| Formoterol 12 mcg | 227 | 26% | 16% | 30% | 7% | |
| Placebo | 225 | 25% | 16% | 33% | 9% | |
| 1222.14 | Olodaterol 5 mcg | 232 | 25% | 23% | 29% | 7% |
| Olodaterol 10 mcg | 234 | 27% | 19% | 27% | 6% | |
| Formoterol 12 mcg | 233 | 25% | 19% | 28% | 9% | |
| Placebo | 235 | 26% | 18% | 26% | 11% | |
| 1222.24a | Olodaterol 5 mcg | 99 | 15%b | 0%b | 18%b | 9% |
| Olodaterol 10 mcg | ||||||
| Formoterol 12 mcg | ||||||
| Placebo | ||||||
| 1222.25a | Olodaterol 5 mcg | 100 | 31%b | 1%b | 12%b | 5% |
| Olodaterol 10 mcg | ||||||
| Formoterol 12 mcg | ||||||
| Placebo | ||||||
| 1222.39a | Olodaterol 5 mcg | 108 | 0% | 8% | 13% | 5% |
| Olodaterol 10 mcg | ||||||
| Tiotropium 18 mcg | ||||||
| Placebo | ||||||
| 1222.40a | Olodaterol 5 mcg | 122 | 0% | 6% | 14% | 9% |
| Olodaterol 10 mcg | ||||||
| Tiotropium 18 mcg | ||||||
| Placebo | ||||||
| B1302 | Indacaterol 150 mcg | 114 | 0% | NR | NR | 0% |
| Indacaterol 300 mcg | 116 | |||||
| Placebo | 117 | |||||
| B2201 | Indacaterol 400 mcg | 68 | 0% | NR | NR | 0% |
| Indacaterol 800 mcg | 67 | |||||
| Placebo | 28 | |||||
| B2354 | Indacaterol 75 mcg | 163 | 0% | 0% | 0% | 0% |
| Placebo | 160 | |||||
| B2355 | Indacaterol 75 mcg | 159 | 0% | 0% | 0% | 0% |
| Placebo | 159 | |||||
| INHANCE | Indacaterol 150 mcg | 420 | 0% | 0% | 0% | 0% |
| Indacaterol 300 mcg | 418 | |||||
| Tiotropium 18 mcg | 420 | |||||
| Placebo | 425 | |||||
| INLIGHT-1 | Indacaterol 150 mcg | 211 | 0% | 0% | 0% | 0% |
| Placebo | 205 | |||||
| INLIGHT-2 | Indacaterol 150 mcg | 333 | 0% | 0% | 0% | 0% |
| Salmeterol 50 mcg | 334 | |||||
| Placebo | 335 | |||||
| INSIST | Indacaterol 150 mcg | 560 | 0% | 0% | 0% | 0% |
| Salmeterol 50 mcg | 563 | |||||
| INTENSITY | Indacaterol 150 mcg | 797 | 0% | 0% | 0% | 0% |
| Tiotropium 18 mcg | 801 | |||||
| INVOLVE | Indacaterol 300 mcg | 437 | 0% | 0% | 0% | 0% |
| Indacaterol 600 mcg | 428 | |||||
| Formoterol 12 mcg | 435 | |||||
| Placebo | 432 | |||||
| INTRUST-1 | Indacaterol 150 mcg | 570 | 100% | 0% | 0% | 0% |
| Placebo | 561 | |||||
| INTRUST-2 | Indacaterol 150 mcg | 572 | 100% | 0% | 0% | 0% |
| Placebo | 570 | |||||
Notes:
a
Cross-over trial
b
unpublished data (on file).
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; IV, intravenous; LAMA, long-acting muscarinic anticholinergic; NR, not reported; SAMA, short-acting muscarinic antagonist.